> According to DEA's data, manufacturers have not fully utilized the APQ for amphetamine in support of domestic manufacturing, reserve stocks, and export requirements for the past three calendar years 2020, 2021 and 2022.
> Based on this trend, DEA has not implemented an increase to the APQ for amphetamine at this time.
Which suggests that the DEA's quota for adderall is not (yet) to blame.
https://www.federalregister.gov/d/2022-26351/p-16
> According to DEA's data, manufacturers have not fully utilized the APQ for amphetamine in support of domestic manufacturing, reserve stocks, and export requirements for the past three calendar years 2020, 2021 and 2022.
> Based on this trend, DEA has not implemented an increase to the APQ for amphetamine at this time.
Which suggests that the DEA's quota for adderall is not (yet) to blame.